Elite Pharmaceuticals, Inc. (ELTP)
OTCMKTS
· Delayed Price · Currency is USD
0.399
-0.001 (-0.25%)
At close: Mar 6, 2026
Elite Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Revenue | 140.12 | 84.04 | 56.63 | 34.16 | 32.26 | 25.38 | Upgrade
|
| Revenue Growth (YoY) | 100.18% | 48.42% | 65.79% | 5.87% | 27.11% | 41.05% | Upgrade
|
| Cost of Revenue | 68.57 | 43.96 | 30.27 | 17.56 | 17.47 | 13.51 | Upgrade
|
| Gross Profit | 71.55 | 40.09 | 26.36 | 16.59 | 14.8 | 11.87 | Upgrade
|
| Selling, General & Admin | 11.93 | 9 | 7.15 | 5.12 | 4.46 | 3.32 | Upgrade
|
| Research & Development | 6.14 | 7.96 | 6.88 | 6.2 | 4.05 | 5.11 | Upgrade
|
| Operating Expenses | 19.86 | 18.88 | 15.57 | 12.63 | 9.72 | 9.76 | Upgrade
|
| Operating Income | 51.68 | 21.2 | 10.79 | 3.97 | 5.07 | 2.1 | Upgrade
|
| Interest Expense | -0.51 | -0.77 | -0.59 | -1.11 | -0.19 | -0.26 | Upgrade
|
| Interest & Investment Income | 0.1 | 0.02 | 0.02 | 0.01 | 0 | 0 | Upgrade
|
| Other Non Operating Income (Expenses) | 5.56 | -18.9 | -11.52 | 0.42 | 1.43 | 1.24 | Upgrade
|
| EBT Excluding Unusual Items | 56.84 | 1.55 | -1.3 | 3.28 | 6.3 | 3.08 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | 1 | - | 0.05 | Upgrade
|
| Asset Writedown | -1.6 | -1.6 | - | -0.29 | - | - | Upgrade
|
| Other Unusual Items | - | - | 1.76 | - | 0.86 | 1.96 | Upgrade
|
| Pretax Income | 55.23 | -0.05 | 0.46 | 3.99 | 7.16 | 5.09 | Upgrade
|
| Income Tax Expense | 11.82 | 4.26 | -19.65 | 0.42 | -1.74 | - | Upgrade
|
| Net Income | 43.41 | -4.31 | 20.11 | 3.56 | 8.9 | 5.09 | Upgrade
|
| Net Income to Common | 43.41 | -4.31 | 20.11 | 3.56 | 8.9 | 5.09 | Upgrade
|
| Net Income Growth | - | - | 464.56% | -59.97% | 74.87% | - | Upgrade
|
| Shares Outstanding (Basic) | 1,071 | 1,068 | 1,015 | 1,013 | 1,011 | 943 | Upgrade
|
| Shares Outstanding (Diluted) | 1,108 | 1,068 | 1,023 | 1,013 | 1,011 | 943 | Upgrade
|
| Shares Change (YoY) | 4.95% | 4.40% | 1.02% | 0.23% | 7.17% | -5.06% | Upgrade
|
| EPS (Basic) | 0.04 | -0.00 | 0.02 | 0.00 | 0.01 | 0.01 | Upgrade
|
| EPS (Diluted) | 0.04 | -0.00 | 0.02 | 0.00 | 0.01 | 0.00 | Upgrade
|
| EPS Growth | - | - | 537.54% | -57.99% | 81.05% | - | Upgrade
|
| Free Cash Flow | 17.24 | 5.83 | -4.04 | -2.4 | 6.01 | 2.86 | Upgrade
|
| Free Cash Flow Per Share | 0.02 | 0.01 | -0.00 | -0.00 | 0.01 | 0.00 | Upgrade
|
| Gross Margin | 51.06% | 47.70% | 46.55% | 48.58% | 45.86% | 46.76% | Upgrade
|
| Operating Margin | 36.89% | 25.23% | 19.05% | 11.62% | 15.72% | 8.29% | Upgrade
|
| Profit Margin | 30.98% | -5.13% | 35.51% | 10.43% | 27.58% | 20.05% | Upgrade
|
| Free Cash Flow Margin | 12.30% | 6.94% | -7.14% | -7.02% | 18.63% | 11.28% | Upgrade
|
| EBITDA | 53.27 | 22.89 | 12.16 | 5.23 | 6.27 | 3.4 | Upgrade
|
| EBITDA Margin | 38.02% | 27.24% | 21.47% | 15.32% | 19.42% | 13.41% | Upgrade
|
| D&A For EBITDA | 1.59 | 1.69 | 1.37 | 1.26 | 1.19 | 1.3 | Upgrade
|
| EBIT | 51.68 | 21.2 | 10.79 | 3.97 | 5.07 | 2.1 | Upgrade
|
| EBIT Margin | 36.89% | 25.23% | 19.05% | 11.62% | 15.72% | 8.29% | Upgrade
|
| Effective Tax Rate | 21.40% | - | - | 10.64% | - | - | Upgrade
|
| Revenue as Reported | 140.12 | 84.04 | 56.63 | 34.16 | 32.26 | 25.38 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.